The US should review Chinese biotech firm WuXi AppTec (藥明康德) and its affiliate WuXi Biologics (Cayman) Inc (藥明生物) for sanctions, a bipartisan group of lawmakers told top officials of the US President Joe Biden’s administration on Monday.
In a letter dated Monday and seen by Reuters, the lawmakers told US Treasury Secretary Janet Yellen, Defense Secretary Lloyd Austin and Commerce Secretary Gina Raimondo that the global pharmaceutical giant’s links to Chinese Communist Party (CCP) and military threatened US national security.
The letter, signed by the Republican chair and Democratic ranking member of the House Select Committee on China, Representatives Mike Gallagher and Raja Krishnamoorthi, and Senators Gary Peters and Bill Hagerty, is Congress’ latest effort to highlight what it says are risks posed by China’s biotech leaders.
Photo: Reuters
Congress has introduced legislation that would restrict federally-funded medical providers from allowing China’s BGI Group (華大集團), WuXi AppTec and other biotech firms from getting genetic information about Americans.
WuXi AppTec did not respond immediately to a request for comment, but has repeatedly said that it is not a national security risk to any country.
“We are concerned by a misguided US legislative initiative to target our company without a fair and transparent review of the facts,” WuXi AppTec said previously in a statement still on its Web site home page.
The four lawmakers — citing public Chinese government documents, Chinese university Web sites and media articles — outlined what they called WuXi AppTec’s clear military ties, as well as support for China’s policies in Xinjiang, a region where Washington has accused Beijing of committing genocide against Muslim minorities.
They said WuXi AppTec had received investment from numerous Chinese People’s Liberation Army (PLA) funds, including the AVIC Military-Civil Integration Selected Hybrid Securities Investment Fund.
They also cited a resume for WuXi Biologics CEO Chen Zhisheng (陳智勝), posted in 2018 to a Tsinghua University Web site, that listed him as a visiting professor at China’s Academy of Military Medical Sciences, which was added to the US Department of Commerce’s export control list in 2021.
“Given WuXi AppTec’s clear ties to the CCP and the PLA and its likely role in enabling the genocide in Xinjiang, we urge your departments to consider the inclusion of WuXi AppTec and its subsidiaries on your respective control lists,” they said in the letter.
Those should include sanctions under Treasury’s Non-SDN Chinese Military-Industrial Complex Companies List, the Commerce list restricting US sales to named entities and the Pentagon’s “1260H” list, which carries implicit warnings about US cooperation with certain firms.
“WuXi AppTec and WuXi Biologics have obscured their ties to the CCP and PLA and, as a result, are rapidly integrating themselves into US supply chains by signing agreements with prominent US biotech entities,” the lawmakers wrote.
The two companies have counted Pfizer Inc, AstraZeneca PLC, GlaxoSmithKline PLC and US national labs as partners.
Shares of contract chipmaker Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) came under pressure yesterday after a report that Apple Inc is looking to shift some orders from the Taiwanese company to Intel Corp. TSMC shares fell NT$55, or 2.4 percent, to close at NT$2,235 on the local main board, Taiwan Stock Exchange data showed. Despite the losses, TSMC is expected to continue to benefit from sound fundamentals, as it maintains a lead over its peers in high-end process development, analysts said. “The selling was a knee-jerk reaction to an Intel-Apple report over the weekend,” Mega International Investment Services Corp (兆豐國際投顧) analyst Alex Huang
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) is expected to remain Apple Inc’s primary chip manufacturing partner despite reports that Apple could shift some orders to Intel Corp, industry experts said yesterday. The comments came after The Wall Street Journal reported on Friday that Apple and Intel had reached a preliminary agreement following more than a year of negotiations for Intel to manufacture some chips for Apple devices. Taiwan Institute of Economic Research (台灣經濟研究院) economist Arisa Liu (劉佩真) said TSMC’s advanced packaging technologies, including integrated fan-out and chip-on-wafer-on-substrate, remain critical to the performance of Apple’s A-series and M-series chips. She said Intel and Samsung
TRANSITION: With the closure, the company would reorganize its Taiwanese unit to a sales and service-focused model, Bridgestone said Bridgestone Corp yesterday announced it would cease manufacturing operations at its tire plant in Hsinchu County’s Hukou Township (湖口), affecting more than 500 workers. Bridgestone Taiwan Co (台灣普利司通) said in a statement that the decision was based on the Tokyo-based tire maker’s adjustments to its global operational strategy and long-term market development considerations. The Taiwanese unit would be reorganized as part of the closure, effective yesterday, and all related production activities would be concluded, the statement said. Under the plan, Bridgestone would continue to deepen its presence in the Taiwanese market, while transitioning to a sales and service-focused business model, it added. The Hsinchu
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) has approved a capital budget of US$31.28 billion for production expansion to meet long-term development needs during the artificial intelligence (AI) boom. The company’s board meeting yesterday approved the capital appropriation plan for purposes such as the installation of advanced technology capacity and fab construction, the world’s largest contract chipmaker said in a statement. At an earnings conference last month, TSMC forecast that its capital expenditure for this year would be at the higher end of the US$52 billion to US$56 billion range it forecast in January in response to robust demand for 5G, AI and
RSS